Galapagos' BioFocus service division will develop compounds against undisclosed inflammation and respiratory targets chosen by Almirall

Galapagos N.V.

Belgium / Small-Cap Biopharma (<$1 billion)

$212.2m on 11/18/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Almirall S.A.

Spain / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced